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Context: Children with cancer, when on treatment and immunosuppressed, are at risk of infection from
live vaccines and do not mount an adequate protective response to inactivated vaccines. Hence,
immunizing them during and after treatment requires special considerations.
Aim: We wanted to assess the current practice of clinicians caring for children with cancer in India
regarding immunisation in these children during and after treatment.
Methods and material: Clinicians from India attending the various pediatric cancer conferences in 2013
were invited to complete a questionnaire.
Statistical analysis used: Data was analysed using software SPSS version 16 and GraphPad InStat version
3.05. Conventional statisticswere used for analysis. Variation inpracticewas assessed by Fisher's exact test.
Results: Responses form 37 institutes (response rate 74%) in 21 cities across India showed that there is
variable practice of immunising childrenwith cancer. There were areas of homogeneity (discontinuing all
live vaccines during treatment and recommencing immunisation six months after end of treatment) and
heterogeneity (continuation of inactivated vaccines and use of the hepatitis B vaccine during treatment).
The variation was seen mainly among clinicians from public and private centres with no signiﬁcant
variation by annual caseload or duration of practice of the responding clinician. Variations were also
observed in relation to sibling and parent vaccination.
Conclusions: There is variation in the immunization practices in India in relation to children with cancer.
Development and dissemination of immunisation guidelines speciﬁc to India would be useful in stan-
dardizing practice.
© 2016 Pediatric Hematology Oncology Chapter of Indian Academy of Pediatrics. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Immunisation for vaccine preventable diseases are important in
children with cancer as it can reduce non-cancer related morbidity
and mortality in these children [1]. Many developed countries have
formulated guidelines for immunising children with cancer during
as well as after the completion of treatment, in line with their
national immunisation schedules [2,3]. However such guidelinesronto. 2) Annual Congress of
aon, 122001, India. Tel.: þ91
Arora).
atology Oncology Chapter of
apter of Indian Academy of Pediat
enses/by-nc-nd/4.0/).from the developing countries are scarce [4]. In the absence of any
such dedicated guidelines in India the immunisation received by
children with cancer remains uncertain due to controversies and
differences in opinion regarding the vaccines as well as their timing
in these children. Till recently, the Indian Academy of Pediatrics
(IAP) Guidebook of Immunisation did not provide any detailed
guidance for immunising these children. The 2014 Guidebook of
Immunisation, however, for the ﬁrst time addresses the issue of
immunisation in children with cancer as part of a chapter dealing
with vaccination in the immunocompromised children [5].
The current study (done before the introduction of the new IAP
guidelines) aims to assess the current practice of clinicians caring
for children with cancer in India regarding immunisation in these
children during and after treatment. We also wanted to determine
immunisation practices for siblings and parents of the children
with cancer during their treatment.rics. Production and hosting by Elsevier B.V. This is an open access article under the
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Clinicians attending the Indian Pediatric Oncology Initiative
meeting in August 2013 were invited to complete a self-
administered questionnaire; participation being fully voluntary.
Based on their responses and feedback the survey questionnaire
was modiﬁed and subsequently administered to clinicians
attending the Indian Pediatric Oncology Group meeting, Pediatric
section of the Indian Cancer Congress all in NewDelhi, India in 2013
and Indian clinicians at the annual conference of the International
Society of Pediatric Oncology held in Hong Kong, China in 2013. One
response was sought per centre. For the purpose of this survey the
questions related to children with cancer who have received
chemotherapy and not those undergoing haematopoietic stem cell
transplantation.
Datawas extracted from the questionnaire entered and analysed
using software SPSS version 16 (Statistical Package for Social Sci-
ences, SPSS, Inc., Chicago IL) and GraphPad InStat version 3.05 for
Windows 95, GraphPad Software, San Diego California USA, www.
graphpad.com. Conventional statistics were used for analysis.
Variation in practice by annual caseload (<100 and >100 new
childhood cancer patients), sector (public and private) and duration
of practice (<10 years and >10 years) was assessed by Fisher's exact
test.
3. Results
Of the 50 institutes contacted, responses from 37 (74%) repre-
senting 21 cities in India were obtained of which 49% were in the
public sector and 46% had an annual caseload of more than 100 new
childhood cancer patients. The characteristics of respondents and
their institutes are displayed in Table 1.
The responses to the questionnaire of the entire study group
(n ¼ 37) are presented in Table 2. Most respondents believed that
live vaccines were contraindicated during treatment. 49% advised
inactivated but not live vaccines and 43% advised no vaccine during
cancer treatment to the child. Clinicians working in private sector
were more likely to stop all vaccinations during treatment (76%) as
opposed to those in the public sector (27%) who would like to
continue inactivated vaccines for majority of their patients
(p ¼ 0.004). 67% recommend hepatitis B vaccine (83% public hos-
pitals, 53% private hospitals, p ¼ 0.08) and 32% annual inﬂuenza
vaccine (25% public hospitals, 42% private hospitals, p¼ 0.48) to the
child undergoing treatment. On exposure to chicken pox, use of
acyclovir was the main prophylactic strategy.Table 1
Characteristics of respondents and their institutes (n ¼ 37).
Duration of practice <5 years 4 (10.8%)
6e10 years 11 (29.7%)
11e15 years 13 (35.1%)
16e20 years 3 (8.1%)
>20 years 6 (16.2%)
Setting of practice Public 18 (48.6%)
Private 19 (51.3%)
Location of practice North India 14 (37.8%)
South India 12 (32.4%)
East India 3 (8.1%)
West India 8 (21.6%)
New patients seen (numbers/year) <25 2 (5.4%)
25e50 4 (10.8%)
51e100 13 (35.1%)
101e200 8 (21.6%)
>200 9 (24.3%)
No response 1 (2.7%)The majority (73%) recommenced immunisation 6 months after
completion of treatment with no signiﬁcant difference between the
two groups in relation to either schedule or timing of re-
immunisation. More than half of the respondents (57%) would
modify the immunisation schedule of siblings, mainly by omitting
the oral polio vaccine or replacing it by the injectable version.
Additional vaccines for siblings and parents were recommended by
a minority of respondents and included inﬂuenza, varicella and
hepatitis B vaccine. No differences of practice in relation to any of
the questions asked were evident among oncologists when
grouped according to the number of years in oncology practice or
by annual caseload.
4. Discussion
Children with cancer remain susceptible to a host of infections
both during and after their treatment due to various disease/
treatment induced immune dysfunctions [1,6]. Many international
agencies have promulgated protocols for immunising these chil-
dren and most of these come from the developed countries
[2,3,7,8]. Until recently there was no evidence based Indian
guideline on immunisation of children with cancer, and practi-
tioners in India had to rely on international guidelines and/or
practice based on scientiﬁc principles. The current study was
therefore planned to identify the practice of clinicians regarding
immunisation of children with cancer during treatment and
following completion of therapy.
Respondents were approached during conferences/meetings
with paper questionnaire as anticipated response to other modes of
survey was low [9]. Only one consultant was approached from any
given institute. Our study group comprised of oncologists with
varied duration of experiences and were from almost all major
regions of the country as well as both public and private institutes.
We recognise that surveys are limited in scope and that stated
practice may not always be true. Nevertheless, surveys are a
convenient tool and have been used elsewhere to determine
practices related to immunising children with childhood cancer
[10e12].
Our study shows that practice of immunising children being
diagnosed with cancer in India varies. This observation of variable
practice is similar to that made in UK and Australia [10,11]. A repeat
survey in UK done after the introduction of Royal College of Pedi-
atrics and Child Health guidelines on immunisation in children
with cancer [3] showed high level of stated compliance with
guidelines and hence consistency in practice [12]. This would
suggest that availability of guidelines has the potential to deliver
uniform immunisation services to these children.
Our survey also identiﬁed areas of homogeneity and heteroge-
neity in practice, particularly between clinicians from public and
private centres. There was no signiﬁcant variation by annual case-
load or duration of practice of the responding clinician. Dis-
continuing all live vaccines during treatment and recommencing
immunisation more than six months after end of treatment were
the main areas of homogeneity. Heterogeneity was observed in the
continuation of inactivated vaccines during cancer treatment and
use of the hepatitis B vaccine during treatment. Historically, high
rates of hepatitis B have been seen in children with cancer after
immunosuppressive treatment, which has attributed to viral
transmission through transfusion of blood products as well as
horizontal transmission through other routes [13,14]. Although our
survey did not directly explore the reasons for variation in practice,
one can hypothesize that the children coming for treatment at
public hospitals would be less likely to be immunised against
hepatitis B and the screening practices of blood donors may not be
as stringent [15]. This may have a bearing on the practices of
Table 2
Survey responses of the participants (n ¼ 37) on immunisation of children with cancer and their contacts.
Questions Responses Number of participants
Immunisation of child with cancer during treatment
Which vaccines are contraindicated during treatment Live vaccines 31 (83.7%)
No response 3 (8.1%)
No vaccines 2 (5.4%)
All vaccines 1 (2.7%)
What advice is given to parents of
children on vaccination during treatment
Can have inactivated vaccines only 18 (48.6%)
Stop all vaccines 16 (43.2%)
Continue routine schedule 1 (2.7%)
HB vaccine only 1 (2.7%)
Decide after one to one discussion 1 (2.7%)
What is the speciﬁc practice on certain vaccines HB vaccine Yes-25 (67.5%)/No-2 (32.5%)
Annual inﬂuenza vaccine Yes-12 (32.5%)/No-23 (62.1%)/Do
not know-2 (5.4%)
What is the practice after varicella (chicken pox) exposure Acyclovir only 21 (56.7%)
VZ Ig þ acyclovir 8 (21.6%)
Nothing speciﬁc 3 (8.1%)
VZ Ig only 2 (5.4%)
Decide after testing antibodies 2 (5.4%)
VZ Ig or acyclovir 1 (2.7%)
Re-immunisation of child with cancer following completion of therapy
How long after completion of treatment do you initiate
revaccination of children with cancer?
>6 months 27 (73%)
>1 year 4 (10.8%)
>3months 3 (8.1%)
Others 3 (8.1%)
What is the strategy for re-immunisation Booster doses for all vaccines 14 (37.8%)
Continue regular schedule 11 (29.7%)
Repeat full schedule 6 (16.2%)
Vaccinate after assessing antibody levels 4 (10.8%)
Do not know 2 (5.4%)
Practice regarding immunisation of sibling/parent of a child with cancer
What is your advice on immunisation for siblings Continue schedule with some modiﬁcations 21 (56.7%)
Continue all vaccines 15 (40.5%)
Stop all vaccines 1 (2.7%)
What speciﬁc additional vaccines do you
recommend for siblings and parents
No vaccines 20 (54%)
Annual inﬂuenza vaccine only 8 (21.6%)
Do not know 4 (10.8%)
Varicella zoster vaccine only 2 (5.4%)
HBþ VZþ Inﬂuenza vaccines 2 (5.4%)
HB vaccine only 1 (2.7%)
HB: hepatitis B, OPV: oral polio vaccine, VZ: varicella zoster, Ig: immunoglobulin.
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sation of the children shortly after diagnosis of cancer as there is
evidence on the effectiveness of this strategy [16].
Acyclovir was the most common strategy for post-exposure
prophylaxis to chicken pox although this practice was not univer-
sal. This variation in practice has also been noted in other settings
with use of varicella zoster immunoglobulin (VZIG) as an alterna-
tive [12,17]. A randomised controlled trial to compare the effec-
tiveness and acceptability of VZIG and aciclovir as PEP against
varicella is both desirable and feasible [18].
In conclusion, this survey demonstrates variability in the cur-
rent practice of clinicians caring for children with cancer in India
regarding immunisation in these children during and after treat-
ment. Development and dissemination of immunisation guidelines
speciﬁc to India, with consideration to local infectious disease
epidemiology, in children who are undergoing or have completed
cancer treatment would be useful in standardizing practice. The
new IAP guidelines are a welcome development in this regard [5].Sources of support
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